A federally-funded study of a drug made by Intercept Pharmaceuticals Inc. was stopped early in January in part because patients taking the drug experienced abnormal cholesterol levels, according to emails between Intercept's chief medical officer and an official at the National Institutes of Health.. The emails, obtained through a public records request, indicate that Intercept was aware as early as Jan. 6 that the cholesterol issue played a role in the NIH's decision to stop the study. In its initial Jan. 9 statement on the...
  